Ligelizumab (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Ligelizumab" in English language version.

refsWebsite

Global rank English rank

6clinicaltrials.gov

5,225^th place

4,062^nd place

5web.archive.org

1^st place

3nih.gov

4^th place

2doi.org

2^nd place

1ama-assn.org

3,257^th place

3,398^th place

1who.int

195^th place

302^nd place

1biospace.com

low place

7,595^th place

1handle.net

102^nd place

76^th place

1pharmatimes.com

low place

1fiercebiotech.com

low place

8,828^th place

ama-assn.org

searchusan.ama-assn.org

Novartis Pharma AG (29 October 2014). "Ligelizumab" (PDF). Statement On A Nonproprietary Name Adopted By The USAN Council. American Medical Association.

biospace.com

"Novartis Ends Phase III Peanut Allergy Trial in Another Flop for Potential Xolair Successor". BioSpace. 2024-01-18. Retrieved 2024-11-29.

clinicaltrials.gov

Clinical trial number NCT02477332 for "A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU)" at ClinicalTrials.gov
Novartis Pharmaceuticals (2023-07-20). A Multi-center, Randomized, Double-blind, Active and Placebo-controlled Study to Investigate the Safety and Efficacy of Ligelizumab (QGE031) in the Treatment of Chronic Spontaneous Urticaria (CSU) in Adolescents and Adults Inadequately Controlled With H1-antihistamines (Report). clinicaltrials.gov. Archived from the original on 2024-10-09. Retrieved 2024-11-29.
Novartis Pharmaceuticals (2024-02-26). A Multi-center, Randomized, Double-blind, Active and Placebo-controlled Study to Investigate the Efficacy and Safety of Ligelizumab (QGE031) in the Treatment of Chronic Spontaneous Urticaria (CSU) in Adolescents and Adults Inadequately Controlled With H1-antihistamines (Report). clinicaltrials.gov. Archived from the original on 2024-10-09. Retrieved 2024-11-29.
Novartis Pharmaceuticals (2024-06-14). A Multi-center, Randomized, Double-blind, Placebo Controlled Study to Investigate the Efficacy and Safety of Ligelizumab (QGE031) in the Treatment of Chronic Inducible Urticaria (CINDU) in Adolescents and Adults Inadequately Controlled With H1-antihistamines (Report). clinicaltrials.gov. Archived from the original on 2024-05-15. Retrieved 2024-11-29.
Novartis Pharmaceuticals (2024-09-13). A 52 Week, Multi-center, Randomized, Double-blind Placebo-controlled Study to Assess the Clinical Efficacy and Safety of Ligelizumab (QGE031) in Decreasing the Sensitivity to Peanuts in Patients With Peanut Allergy (Report). clinicaltrials.gov.
Novartis Pharmaceuticals (2024-11-14). A Three-year, Multi-center, Double-blind, Extension Study to Evaluate the Long-term Safety and Efficacy of Ligelizumab in Patients Who Completed Ligelizumab's Phase III Studies in Food Allergy (Report). clinicaltrials.gov.

doi.org

Kocatürk E, Maurer M, Metz M, Grattan C (2017-01-10). "Looking forward to new targeted treatments for chronic spontaneous urticaria". Clinical and Translational Allergy. 7: 1. doi:10.1186/s13601-016-0139-2. PMC 5223554. PMID 28078079.
Maurer M, Giménez-Arnau AM, Sussman G, Metz M, Baker DR, Bauer A, et al. (October 2019). "Ligelizumab for Chronic Spontaneous Urticaria". The New England Journal of Medicine. 381 (14): 1321–1332. doi:10.1056/NEJMoa1900408. hdl:10230/43837. PMID 31577874.

fiercebiotech.com

Taylor, Nick Paul (2021-12-20). "Novartis suffers shock setback as Xolair successor fails phase 3 | Fierce Biotech". www.fiercebiotech.com. Retrieved 2024-11-29.

handle.net

hdl.handle.net

Maurer M, Giménez-Arnau AM, Sussman G, Metz M, Baker DR, Bauer A, et al. (October 2019). "Ligelizumab for Chronic Spontaneous Urticaria". The New England Journal of Medicine. 381 (14): 1321–1332. doi:10.1056/NEJMoa1900408. hdl:10230/43837. PMID 31577874.

nih.gov

pubmed.ncbi.nlm.nih.gov

Kocatürk E, Maurer M, Metz M, Grattan C (2017-01-10). "Looking forward to new targeted treatments for chronic spontaneous urticaria". Clinical and Translational Allergy. 7: 1. doi:10.1186/s13601-016-0139-2. PMC 5223554. PMID 28078079.
Maurer M, Giménez-Arnau AM, Sussman G, Metz M, Baker DR, Bauer A, et al. (October 2019). "Ligelizumab for Chronic Spontaneous Urticaria". The New England Journal of Medicine. 381 (14): 1321–1332. doi:10.1056/NEJMoa1900408. hdl:10230/43837. PMID 31577874.

ncbi.nlm.nih.gov

Kocatürk E, Maurer M, Metz M, Grattan C (2017-01-10). "Looking forward to new targeted treatments for chronic spontaneous urticaria". Clinical and Translational Allergy. 7: 1. doi:10.1186/s13601-016-0139-2. PMC 5223554. PMID 28078079.

pharmatimes.com

Parsons, Lucy (2021-01-15). "US breakthrough designation for ligelizumab in chronic spontaneous urticaria - PharmaTimes". pharmatimes.com. Archived from the original on 2023-06-03. Retrieved 2024-11-29.

web.archive.org

"International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107" (PDF). WHO Drug Information. 26 (2). 2012. Archived (PDF) from the original on 2016-03-04. Retrieved 2020-10-05.
Parsons, Lucy (2021-01-15). "US breakthrough designation for ligelizumab in chronic spontaneous urticaria - PharmaTimes". pharmatimes.com. Archived from the original on 2023-06-03. Retrieved 2024-11-29.
Novartis Pharmaceuticals (2023-07-20). A Multi-center, Randomized, Double-blind, Active and Placebo-controlled Study to Investigate the Safety and Efficacy of Ligelizumab (QGE031) in the Treatment of Chronic Spontaneous Urticaria (CSU) in Adolescents and Adults Inadequately Controlled With H1-antihistamines (Report). clinicaltrials.gov. Archived from the original on 2024-10-09. Retrieved 2024-11-29.
Novartis Pharmaceuticals (2024-02-26). A Multi-center, Randomized, Double-blind, Active and Placebo-controlled Study to Investigate the Efficacy and Safety of Ligelizumab (QGE031) in the Treatment of Chronic Spontaneous Urticaria (CSU) in Adolescents and Adults Inadequately Controlled With H1-antihistamines (Report). clinicaltrials.gov. Archived from the original on 2024-10-09. Retrieved 2024-11-29.
Novartis Pharmaceuticals (2024-06-14). A Multi-center, Randomized, Double-blind, Placebo Controlled Study to Investigate the Efficacy and Safety of Ligelizumab (QGE031) in the Treatment of Chronic Inducible Urticaria (CINDU) in Adolescents and Adults Inadequately Controlled With H1-antihistamines (Report). clinicaltrials.gov. Archived from the original on 2024-05-15. Retrieved 2024-11-29.

who.int

"International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107" (PDF). WHO Drug Information. 26 (2). 2012. Archived (PDF) from the original on 2016-03-04. Retrieved 2020-10-05.